Quantum-si Stock Earnings Reports

Quantum-Si provided a product and financial update focused on advancing its next-generation Proteus single-molecule protein sequencing platform while conserving cash. Key operational takeaways: (1) Technical progress — management reported successful end-to-end sequencing runs on fully integrated Proteus prototypes, with developmental reagents/arrays that now detect 17 amino acids (up from 15 in Dec 2025), improved detection frequency, ~2x read length vs. Platinum in customer tests, and no major technical gating issues remaining. They expect Proteus to detect 18 amino acids by the commercial launch (targeted in 2026), demonstrate all 20 amino acids during 2026, and deliver a 20-amino-acid sequencing kit in 2027. Proteus is presented as higher throughput, more automated, and offering better signal-to-noise enabling broader applications (especially post-translational modification (PTM) detection and variant analysis). Management emphasized kinetic-signature–based PTM detection combined with AI analytics as a major capability. (2) Commercial preparation — roadshow series and early-access/sample-evaluation programs underway to build demand and customer funnel; internal R&D fleet expansion and partnerships to support sample evaluations and early access sites (a “handful” expected by summer). Proteus pricing was reiterated as $425k and early feedback has been constructive. (3) Financials — Q1 revenue was $0.258M, gross margin 29%; GAAP operating expense $24.1M (adjusted $21.4M). Cash, cash equivalents and marketable securities were $190.4M at 3/31/2026. 2026 outlook reiterated: revenue ~ $1M, adjusted operating expenses ≤ $98M, total cash usage ≤ $93M. Management says they have cash runway into 2028 and will preserve financial strength while funding Proteus completion and commercial readiness. Overall investor implications: technical de-risking is progressing materially, commercial go-to-market activities are ramping (sample evaluations, roadshows, early access), and the company is managing cash conservatively with a multi-year runway ahead of anticipated revenue scale-up driven by Proteus consumable utilization post-launch.